Cargando…

A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes

SIMPLE SUMMARY: To overcome the limitations of intraperitoneal chemotherapy (IP), which include a low completion rate and port-related toxicities, we modified three institutional procedures concerning IP chemotherapy in patients with ovarian cancer: (i) insertion of an IP port in a neutral abdominal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ji Hyun, Ha, Hyeong In, Kim, Min Hae, Han, Mi Ra, Park, Sang-Yoon, Lim, Myong Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508040/ https://www.ncbi.nlm.nih.gov/pubmed/34638370 http://dx.doi.org/10.3390/cancers13194886

Ejemplares similares

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)
por: Kim, Ji Hyun, et al.
Publicado: (2022)

Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R)
por: Yoo, Ji Geun, et al.
Publicado: (2023)

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Yoon, Ji-Young, et al.
Publicado: (2014)

Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
por: Ko, Jieun, et al.
Publicado: (2021)

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
por: Lim, Myong Cheol, et al.
Publicado: (2022)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
por: Kim, Myung Joo, et al.
Publicado: (2012)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer
por: Kim, S.I., et al.
Publicado: (2021)

Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons
por: Yoo, Heon Jong, et al.
Publicado: (2018)

Anaesthesia considerations and techniques for Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC)
por: Shree, Venkatesan, et al.
Publicado: (2020)

Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea
por: Kim, Se Ik, et al.
Publicado: (2022)

Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
por: Wu, Tao, et al.
Publicado: (2018)

Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study
por: Kim, Ji Hyun, et al.
Publicado: (2022)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
por: Fujiwara, Keiichi
Publicado: (2012)

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
por: Helm, C. William
Publicado: (2015)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?
por: Spiliotis, John
Publicado: (2020)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Huffman, Olivia G., et al.
Publicado: (2023)

How to make the best strategy to manage thromboembolism in ovarian cancer?
por: Lim, Myong Cheol, et al.
Publicado: (2012)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
por: Spiegelberg, Julia, et al.
Publicado: (2020)

Peritoneal cancer index in ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
por: Lee, Yong Jae, et al.
Publicado: (2022)

DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study
por: FENG, ZENG-LI, et al.
Publicado: (2015)

Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis
por: Tang, Qin, et al.
Publicado: (2023)

Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy
por: Chan, Daniel L, et al.
Publicado: (2012)

Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer
por: Chambers, Laura Moulton, et al.
Publicado: (2019)

Evaluation of a Novel Prototype for Pressurized Intraperitoneal Aerosol Chemotherapy
por: Lee, Hee Su, et al.
Publicado: (2020)

Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum
por: Park, Soo Jin, et al.
Publicado: (2021)

The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry
por: Ha, Hyeong In, et al.
Publicado: (2021)

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer
por: Seagle, Brandon-Luke L., et al.
Publicado: (2016)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
por: Glennon, Kate, et al.
Publicado: (2021)

Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer
por: Chambers, Laura M., et al.
Publicado: (2022)

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
por: Mishra, Mona, et al.
Publicado: (2021)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Assessment of Hyperthermic Intraperitoneal Chemotherapy to Eradicate Intraperitoneal Free Cancer Cells()
por: Ji, Zhonghe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1pms0v61mn2nei6114j4k56fsv